Who are EpiCept-NP-1 Cream's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Qutenza Patch, Capsaicine low dose 0.04 %, Topical capsaicin, Pain Relief Ointment, Relief Pro cream, Capsaicin 8%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epicept-np-1-cream.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

EpiCept-NP-1 Cream — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EpiCept-NP-1 Cream (EpiCept-NP-1 Cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical analgesic. Area: Pain management.

phase 2 Topical analgesic Neutral endopeptidase (NEP) Pain management Small molecule Live · refreshed every 30 min

Target snapshot

EpiCept-NP-1 Cream (EpiCept-NP-1 Cream) — EpiCept Corporation. EpiCept-NP-1 Cream is a topical analgesic that works by blocking the production of substance P, a neuropeptide involved in pain transmission.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EpiCept-NP-1 Cream TARGET	EpiCept-NP-1 Cream	EpiCept Corporation	phase 2	Topical analgesic	Neutral endopeptidase (NEP)
Qutenza Patch	Qutenza Patch	M.D. Anderson Cancer Center	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Capsaicine low dose 0.04 %	Capsaicine low dose 0.04 %	University Hospital, Clermont-Ferrand	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Topical capsaicin	Topical capsaicin	The University of Texas Health Science Center, Houston	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Pain Relief Ointment	Pain Relief Ointment	Johnson & Johnson Consumer and Personal Products Worldwide	marketed	Topical analgesic
Relief Pro cream	Relief Pro cream	Bayer	marketed	Topical analgesic
Capsaicin 8%	Capsaicin 8%	Averitas Pharma, Inc.	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical analgesic class)

Bayer · 1 drug in this class
EpiCept Corporation · 1 drug in this class
Express Specialty Pharmacy · 1 drug in this class
Georg Kägi, MD · 1 drug in this class
Grünenthal GmbH · 1 drug in this class
Henry Ford Health System · 1 drug in this class
Johnson & Johnson Consumer and Personal Products Worldwide · 1 drug in this class
NeurogesX · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EpiCept-NP-1 Cream — Competitive Intelligence Brief. https://druglandscape.com/ci/epicept-np-1-cream. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab